Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1995-10-19
1997-10-14
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514549, 514551, 514552, 514 63, 424450, A61K 3122, A61K 9127
Patent
active
056773374
ABSTRACT:
This invention provides a compound having the formula R.sup.1 --Y.sup.1 --CHZ.sup.1 --CH(NY.sup.2 Y.sup.3)--CH.sub.2 --Z.sup.2, wherein: R.sup.1 is a straight-chained alkyl, alkenyl or alkynyl group having from 8 to 19 carbon atoms in the aliphatic chain; Y.sup.1 is --CH.dbd.CH--, --C.tbd.C-- or --CH(OH)CH(OH)--; Z.sup.1 is OH or a conversion-inhibiting group; Z.sup.2 is a conversion-inhibiting group; Y.sup.2 is H, a phenyl group, an alkyl-substituted phenyl group having from 1 to about 6 carbons in the alkyl chain, or an alkyl chain having from 1 to 6 carbons; Y.sup.3 is H or a group having the formula --C(O)R.sup.2 or --S(O).sub.2 R.sup.2 ; R.sup.2 is a straight-chained alkyl, alkenyl or alkynyl group having from 1 to 23 carbon atoms in the chain; and when Z.sup.2 is an amino, R.sup.2 is an aliphatic chain having from 1 to 9 or from 19 to 23 carbon atoms in the aliphatic chain.
REFERENCES:
patent: 4522803 (1985-06-01), Lenk et al.
patent: 4588578 (1986-05-01), Fountain et al.
patent: 4721612 (1988-01-01), Janoff et al.
patent: 4975282 (1990-12-01), Cullis et al.
patent: 5008050 (1991-04-01), Cullis et al.
patent: 5030453 (1991-07-01), Lenk et al.
patent: 5059421 (1991-10-01), Loughrey et al.
patent: 5077056 (1991-12-01), Bally et al.
patent: 5100662 (1992-03-01), Bolcsak et al.
patent: 5169637 (1992-12-01), Lenk et al.
Okashi et al. Tetrahedron Letters 29, #10, pp. 1189-1192, 1988.
Bangham, et al., "Diffusion of Univalent Ions across the Lamellae of Swollen Phospholipids", J. Mol. Bio. 13:238-252, 1965.
Baringa, M. . "Death Gives Birth to the Nervous System. But How?", Science, 259, 762-763, 1993.
Cohen, J., "Overview: Mechanisms of apoptossis", Immunology Today, 14(3), 1993, 126-130.
Cohen, J. "Programmed Cell Death in the Immune System", Advances in Immunology, 50, 55-85, 1991.
Cullis, et al., in:Liposomes, From Biophysics to Therapeutics (M. J. Ostro, ed., ), Marcel Dekker, pp. 39-72 (1987).
Dbaibo, et al., "Tumore Necrossis Factor -.alpha.(TNF-.alpha.) Signal Transduction through Ceramide", J. Biol. Chem. 268(24), 17762-17766, 1993.
Fesus, et al., "Apoptosis: molecular mechanisms in programmed cell death", European J. of Cell Biology, 56, 170-177, 1991.
Fishbein et al., "Ceramide-mediated Growth Inhibition and CAPP are Conserved in Saccharomyces cerevissiae", J. Biol. Chem., 268(13), 9255-9261, 1993.
Gronberg, et al., "Interaction of Cholesterol with Synthetic Sphingomyelin Derivatives in Mixed Monolayers", Biochemistry, 1991, 30, 10746-10754.
Kabelitz, et al., "Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes", Immunology Today, 14(7), 1993, 338-.
Kan, et al., "Interaction of Cholesterol with Sphingomyelin in Bilayer membranes: Evidence that the Hydroxy Group of Sphingomyelin Does Not Modulate the Rate of Cholesterol Exchange between Vesicles", Biochemistry, 1991, 30, 7759-7766.
Kim, et al., "Identification of Sphingomyelin Turnover as an Effector Mechanism for the Action of Tumor Necrosis Factor .alpha. and .gamma.-Interferon", J. Biol. Chem. 266(1), 484-489, 1991.
Kolesnick, R., "Ceramide: a novel second messenger", Trends in Cell Biology, 2, 1992, 232-236.
Martin, S., "Apoptosis: suicide, execution or murder?", Cell Biology Trends.
Marx, J., "Cell Death Studies Yield Cancer Clues", Science, 259:760-1 (1993).
Morishige, et al., "In vitro cytostatic effect of TNF (Tumore Necrosis Factor) entrapped in immunoliposomes on cells normally insecsitive to TNF", BBA, 1151 (1993) 59-68.
Obeid, et al., "Programmed Cell Death Induced by Ceramide", Science, 259, 1769-1771, 1993.
Ohashi, et al., "Synthesis of Phophonophingoglycolipid Found in Marine Snail Turbo Cornutus", Tetrahedron Letters, 29(10): 1189-1192, 1988.
Papahadjopoulos et al.., "Phospholipid Model Membranes, I. Structural Characteristic of Hydrated Liquid Crystals", Biochim. Biophys Acta 1967; 135:624-638.
Raines, et al., "Sphingomyelinase and Ceramide Activate Mitogen-activated Protein Kinase in Myeloid HL-60 Cells", J. Biol. Chem., 268(20), 14572-14575, 1993.
Stedman's Medical Dictionary (Illustrated), (24th edition J. V. Basmajian et al., eds.) Williams and Wilkins, Baltimore, MD, 1982, p. 99.
Sugimoto, et al., "Preparation of sphingosine derivatives as antitumor agents", Chemical Abstracts, 1990, 112:566573n.
Vilcek, et al., "Tumor Necrosis Factor, New Insights into the Molecular Mechanissms of its Multiple Actions", J. Biol. Chem., 266(12), 7313-7316, 1991.
Williams, et al., "Apoptosis: final control point in cell biology", Trends in Cell Biology, 2, 263-267, 1992.
Williams, et al., "Molecular Regulation of Apoptosis: Genetic Contols on Cell Death", Cell, 74, 777-779, 1993.
Lukevics, E., "Biological Activity of nitrogen-containing organosilicon compounds", Nobel Symp. 1977 (pub. 1978) Biochem. Silicon, Relat. Probl., 40, 435-437.
Ahmad Imran
Janoff Andrew S.
Mayhew Eric
Wei Yong
Kishore Gollamudi S.
Rubin Kenneth B.
The Liposome Company Inc.
LandOfFree
Methods of treatment using pharmaceutically active ceramide-rela does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment using pharmaceutically active ceramide-rela, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using pharmaceutically active ceramide-rela will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1555805